Skip to main content
Clinical Trials

POE16-01, A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Hematologic Malignancies Identifier


For more information about this study
View Details

About This Study

This is a multi-center, open label, phase I/II trial evaluating the safety and efficacy of neratinib in pediatric patients with relapsed/refractory malignancies. This trial is an investigator initiated trial managed by the Pediatric Oncology Experimental Therapeutics Investigator s Consortium (POETIC), which will hereafter be referred to as the Sponsor. In the phase I portion, the primary objective will be to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for neratinib in pediatric patients with relapsed/refractory malignancies. There will be 2 cohorts of patients, which will accrue separately: Cohort 1 will consist of patients with solid tumors including lymphoma and central nervous system (CNS) malignancies, and will accrue first. Cohort 2 will consist of patients with relapsed/refractory acute leukemia. Once an MTD has been determined in Cohort 1, Cohort 2 will begin enrolling with a limited dose-escalation design at the MTD found in cohort 1. Additionally, an interim analysis will be performed after the completion of enrollment of Cohort 1 at which time the toxicity profile, PK and PD data will be reviewed to establish confidence regarding the RP2D to be used for the starting dose of the leukemia cohort and for subsequent dosing of solid tumor patients. A rolling six dose escalation schema will be used with 3-6 subjects enrolled per dose level for both cohorts. Patients are recommended to be admitted for the first 7 days of Cycle 1 to monitor for diarrhea. If the patient is treated in an outpatient setting, they must be seen every 48- 72hours. Patients must be able to swallow tablets for eligibility onto the study. Neratinib will be administered once a day either by mouth or via a pre-existing permanent gastrostomy tube. Each cycle will consist of 28 days. There will be no interruption of dosing between Day 28 of Cycle 1 and Day 1 of Cycle 2. Dose escalation is detailed in Appendix 2 and will continue until MTD and RP2D is established. There will be no intra-patient dose escalation. It is anticipated that the phase I part for Cohort 1 will be completed in 1 year. The phase I part for Cohort 2 is anticipated to take less than a year to accrue since these patients will utilize a limited doseescalation schema and will start accrual either at the MTD identified for Cohort 1 or, if unacceptable toxicity is noted at the MTD in the interim analysis, one dose level below. We anticipate accruing 9-12 patients in Cohort 2. The expected accrual for the phase 1 component is 18-30 patients overall. Once the MTD is established in Cohort 1, the phase II portion of the study will open for accrual for solid tumors (including lymphoma and CNS malignancies) at the RP2D following a Simon two stage design. These patients will accrue simultaneously with the accrual of Cohort 2 patients to the phase I portion. Once the MTD for Cohort 2 is identified, this dose level will be moved into the phase II part of the study for leukemia patients only. The phase II part is expected to accrue 12-29 patients over the course of 1.5 years, with the leukemia patients expected to enter this phase while accrual for solid tumor is already occurring.